ADmit Therapeutics — Series A (estimated) · €5.4M

The IDIBELL spin-off, which uses mitochondrial DNA methylation patterns in blood to predict which mild-cognitive-impairment patients will progress to Alzheimer's, raised a €5.4M equity round led by Clave Capital through its Clave Innohealth fund. Proceeds go towards CE marking and FDA approval for its MAP-AD test in Europe and the United States.

LeadClave Capital RoundSeries A (estimated) Announced6 Oct 2023 CityEsplugues de Llobregat · reported L'Hospitalet de Llobregat SectorHealthtech & Bio · Biotech / Diagnostics Source I A

Something wrong? Suggest a correction →